Overcoming prostate cancer drug resistance with a novel organosilicon small molecule

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Discovery

Background:

• Advanced prostate cancer (PCa) poses treatment challenges due to resistance to androgen-deprivation therapy (ADT) and chemotherapy.
• Developing novel therapies is crucial to overcome drug resistance and improve patient outcomes in PCa.

Purpose of the Study:

• To evaluate a novel class of organosilicon compounds for anticancer activity against drug-resistant PCa.
• To investigate the mechanism of action of promising compounds, focusing on their molecular targets and effects on resistant PCa cells.

Main Methods:

• Screening of five organosilicon compounds against the NCI-60 panel and drug-resistant PCa cell lines.
• Molecular studies to identify targets, including androgen receptor (AR), AR variant 7 (AR-v7), and survivin.
• In vivo efficacy studies using subcutaneous and intraosseous xenograft models of ADT-resistant and chemoresistant PCa.

Main Results:

• GH1504 demonstrated potent in vitro cytotoxicity across various cancer cells, including ADT- and chemotherapy-refractory PCa cells.
• GH1504 was found to target AR, AR-v7, and survivin, potentially by promoting their protein turnover and inducing apoptosis.
• In vivo studies showed significant inhibition of tumor growth in both ADT-resistant and chemoresistant PCa xenograft models.

Conclusions:

• GH1504 exhibits significant preclinical efficacy against drug-resistant prostate cancer.
• The compound's mechanism involves targeting key proteins like AR, AR-v7, and survivin.
• GH1504 represents a promising therapeutic lead for developing novel treatments for resistant PCa.